“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial looking at LY2940680 for small cell lung cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a new drug called LY2940680 with carboplatin and etoposide chemotherapy for small cell lung cancer that has spread beyond the lungs.
Doctors usually use chemotherapy to treat small cell lung cancer that has spread beyond the lungs (extensive disease). One combination of drugs they use is carboplatin and etoposide. This combination works but researchers are always looking for ways to improve treatment.
In this trial some people will have LY2940680 with carboplatin and etoposide. And some will have a dummy drug (
The aims of this trial are to find out
- The best dose of LY2940680 to give with carboplatin and etoposide
- How well LY2940680, carboplatin and etoposide works for people with extensive stage small cell lung cancer
- What are the side effects of LY2940680, carboplatin and etoposide
Who can enter
You may be able to enter this trial if you
- Have small cell lung cancer that has spread beyond the lung (extensive stage)
- Are well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1)
- Have at least 1 area of cancer that is 20mm in size or more on an ordinary CT scan or, 10mm or more on a spiral CT scan (your doctor can tell you this)
- Have adequate blood tests results
- Are able to swallow capsules
- Are willing to use reliable contraception during treatment and for 6 months afterwards if you or your partner could become pregnant
- Are at least 18 years old
You cannot enter this trial if
- You also have non small cell lung cancer (NSCLC)
- Your cancer has spread to your brain or spinal cord and you have symptoms or use steroids to control symptoms. If you had radiotherapy for your cancer spread more than 2 weeks ago, have not used steroids for more than a week and your condition is stable, you may be able to take part
- You have had a treatment that reaches your whole body (
- You have had radiotherapy to more than a quarter of your
bone marrow(your doctor can tell you this)
- You have had radiotherapy to all of your chest or all of the area between your hip bones (pelvis)
- You have had radiotherapy in the past 2 weeks
- You are already taking part in another clinical trial or have done so in the past month
- You have already had LY2940680
- You have an infection
- You have had a heart attack in the past 6 months or have another serious heart problem
- You have had a vaccine for yellow fever in the past month
- You have had another cancer in the past 5 years apart from carcinoma in situ of the cervix, non melanoma skin cancer or prostate cancer that hasn’t spread to another part of your body
- You have a build up of fluid between your chest wall and lungs (pleural effusion) or in your abdomen (ascites) that can’t be controlled
- You have lost a lot of weight in the past 6 weeks
- You are taking any other cancer medication apart from hormone therapy for prostate cancer that hasn’t spread or hormone therapy for breast cancer
- You are taking any other medication that affects body proteins called cytochrome P enzymes (your doctor can tell you this)
- You are pregnant or breastfeeding
This is a phase 1/2 trial. It will recruit 132 people. The trial is in 2 parts.
In part 1, the first few people will have a low dose of LY2940680 with carboplatin and etoposide. If they don’t have any serious side effects, the next few people will have a higher dose. And so on, until they find the best dose of LY2940680 to give with carboplatin and etoposide. This is called a dose escalation study.
Part 2 is a randomised trial. The people taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in. And neither of you will know which group you are in. This is called a double blind trial.
The treatment groups are
- Carboplatin, etoposide and LY2940680 (you have double the chance of being put into this group)
- Carboplatin, etoposide and dummy drug (placebo)
LY2940680 and the dummy drug are capsules. You take them 4 times every day for 3 weeks and then have a week of not taking them. Each 4 week period is called a cycle of treatment.
You have etoposide and carboplatin as an injection into a vein. You have etoposide on the first 3 days of each 4 week cycle of treatment. You have carboplatin on the first day of each cycle. You have 6 cycles of treatment.
After 6 cycles your doctor may talk to you about having radiotherapy to your head to kill off any cancer cells that may have spread to your brain. This is called prophylactic cranial irradiation (PCI). And then they may talk to you about continuing with LY2940680 or the dummy drug. You continue having treatment as long as it is helping you and the side effects aren’t too bad.
The researchers will ask for a sample of your cancer that was removed when you had surgery or a
If you take part in the 2nd part of the trial, the trial team will ask you to fill out a questionnaire before you start treatment, every 4 weeks during treatment and after you finish treatment. The questionnaire will ask about side effects and how you’ve been feeling. This is called a quality of life study.
You see the doctor to have some tests before taking part in this trial. These tests include
During treatment you see the doctor every 4 weeks for the same tests, apart from the heart trace. You have a CT scan or MRI scan every 6 to 8 weeks.
You see the doctor for the same tests (apart from the heart trace) a month after finishing treatment and then every 3 months.
How to join a clinical trial
Dr Martin Forster
Eli Lilly and Company Limited
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer